Sales for chronic hepatitis B therapeutics 2014 and 2024 by major market

This statistic shows the chronic hepatitis B therapeutics sales in 2014 and 2024, by major market. Sales for chronic hepatitis B therapeutics in the U.S. market were some 773 million U.S. dollars in 2014.

Chronic hepatitis B therapeutics sales in selected major markets in 2014 and 2024

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
in the first 12 months
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

2016

Region

Worldwide

Survey time period

as of January 2016

Supplementary notes

All data is based on primary research interviews and surveys conducted with key opinion leaders (KOLs) and high-prescribing physicians in the countries included in this report.
* Forecast.
** EU5: Five major European pharmaceutical markets (France, Germany, Italy, Spain, and UK).

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical industry in Norway "

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.